Leerink Partners analyst Joseph Schwartz downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE